Propensity-matched TriNetX cohorts (669 pairs) of TP53–wild-type, treatment-naive CLL showed venetoclax–obinutuzumab improved TTNT and 4-year OS versus acalabrutinib (HR 1.84). Median TTNT was 47.7 ...

Studies of obinutuzumab, a type II anti-CD20 antibody, have shown efficacy in the treatment of hematologic cancers and autoimmune diseases. An evaluation of the efficacy and safety of obinutuzumab in ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. It looks like Trafalgar Releasing is set to release yet another K-pop live viewing concert!

Please provide your email address to receive an email when new articles are posted on . Obinutuzumab bested placebo in SRI-4 response in adults with systemic lupus erythematosus. The results provide a ...

The anti-CD20 therapeutic antibody obinutuzumab (Gazyva/Gazyvaro) significantly reduces multiple measures of disease activity when compared with placebo in people with active systemic lupus ...

Obinutuzumab is a potent anti-B cell drug already approved to treat lupus nephritis, chronic lymphocytic leukemia, and follicular lymphoma. Therapies targeting B cells are perhaps the most effective ...

A significantly greater percentage of patients achieved complete remission with obinutuzumab vs with tacrolimus at 104 weeks. Topline results were announced from a phase 3 trial evaluating ...

Former Utah signee Salesi Moa, ESPN's No. 6 wide receiver and No. 38 overall prospect in the 2026 class, will sign with Michigan out of the transfer portal, he announced Friday. A 6-foot-2, 185-pound ...

Findings showed a higher percentage of participants on obinutuzumab achieved a minimum 4-point improvement in SRI-4 at 52 weeks vs standard therapy. Topline data were announced from a phase 3 trial ...